Evolva is focused on the research, development and commercialisation of natural ingredients derived from yeast for applications across the flavours and fragrances, health Ingredients cosmetics and health protection sectors
Lallemand Inc, a global leader in industrial biotechnology has confirmed the closing in December 2023 of the acquisition by its subsidiary Danstar Ferment AG of Swiss biotechnology business Evolva AG from Evolva Holding AG.
The transaction which was originally announced to the Swiss Stock Exchange on 21 November 2023 was approved by Evolva Holding shareholders at an extraordinary general meeting on 21st December 2023.
Evolva is focused on the research, development and commercialisation of natural ingredients derived from yeast for applications across the flavours and fragrances, health Ingredients cosmetics and health protection sectors. Evolva is headquartered in Reinach, Basel with 48 employees.
Lars Asferg, President of Lallemand Bio-Ingredients said: “Evolva offers us a strong strategic fit with our yeast-based technology platform. Evolva’s proprietary precision fermentation technology and R&D capabilities present an ideal platform from which to expand our product offering mainly within health ingredients like Veri-te resveratrol and flavour & fragrance aroma components like Valencene and natural Nootkatone. We look forward to welcoming the Evolva employees into our Lallemand family and continuing to work with suppliers, and existing and new customers in bringing sustainable, yeast-based ingredients based to markets globally via Lallemand’s extensive commercial and operational network”.